New drug IPH4502 targets Hard-to-Treat cancers in early trial

NCT ID NCT06781983

Recruiting now Disease control Sponsor: Innate Pharma Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated May 08, 2026 · Updated 18 times

Summary

This early-phase study tests a new drug called IPH4502 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Nectin-4 found on many cancer cells. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Léon Bérard
RECRUITING

Lyon, 69008, France

Contact
Gustave Roussy Cancer Institute
RECRUITING

Villejuif, 94805, France

Contact
John Theurer Cancer Center
RECRUITING

Hackensack, New Jersey, 07601, United States

Contact
Massachusetts General Hospital - Boston
RECRUITING

Boston, Massachusetts, 02114, United States

Contact
Mount Sinai Tisch Cancer Center
RECRUITING

New York, New York, 10029, United States

Contact
NEXT Oncology - Dallas
RECRUITING

Dallas, Texas, 75039, United States

Contact
NEXT Oncology - Virginia
RECRUITING

Fairfax, Virginia, 22031, United States

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC SOLID TUMORS